Поиск | Bundas24

Mike Warn добавлена новая статья Shopping
2025-07-15 03:52:22 -

Anaplastic Lymphoma Kinase Metastatic Non-Small Cell Lung Cancer Market Scope: Growth, Share, Value, Insights, and Trends
"Executive Summary Anaplastic Lymphoma Kinase Metastatic Non-Small Cell Lung Cancer Market : The global anaplastic lymphoma kinase metastatic non-small cell lung cancer market was valued at USD 2.14 billion in 2024 and is expected to reach USD 3.65 billion by 2032 During the forecast period of 2025 to 2032 the market is likely to grow at a CAGR of...

0 Комментарии 0 Поделились 210 Просмотры 0 предпросмотр

Войдите, чтобы отмечать, делиться и комментировать!
Aryan Mhatre добавлена новая статья Другое
2025-07-11 09:05:38 -

Metastatic Castrate Resistant Prostate Cancer Treatment Market Companies: Growth, Share, Value, Size, and Insights
"Executive Summary Metastatic Castrate Resistant Prostate Cancer Treatment Market : The global metastatic castrate resistant prostate cancer treatment market size was valued at USD 11.99 billion in 2024 and is expected to reach USD 22.37 billion by 2032, at a CAGR of 8.10% during the forecast period This Metastatic Castrate Resistant Prostate Cancer...

0 Комментарии 0 Поделились 251 Просмотры 0 предпросмотр

Войдите, чтобы отмечать, делиться и комментировать!
Aryan Mhatre добавлена новая статья Другое
2025-06-24 06:24:11 -

Metastatic Castrate Resistant Prostate Cancer Treatment Market Leaders: Growth, Share, Value, Size, and Scope
"Executive Summary Metastatic Castrate Resistant Prostate Cancer Treatment Market : The global metastatic castrate resistant prostate cancer treatment market size was valued at USD 11.99 billion in 2024 and is expected to reach USD 22.37 billion by 2032, at a CAGR of 8.10% during the forecast period A credible Metastatic Castrate Resistant...

0 Комментарии 0 Поделились 396 Просмотры 0 предпросмотр

Войдите, чтобы отмечать, делиться и комментировать!
Kislay Kumar добавлена новая статья Другое
2025-06-09 13:55:31 -

Metastatic Colorectal Cancer Market is driven by Advancements in Targeted Therapies
Metastatic Colorectal Cancer therapies encompass targeted biologics, immunotherapies, and combination regimens designed to inhibit EGFR and VEGF signaling pathways. Monoclonal antibodies such as cetuximab and panitumumab enhance progression-free survival, while novel small molecule inhibitors offer improved oral bioavailability and tolerability. Biomarker-driven platforms, including KRAS and...

0 Комментарии 0 Поделились 500 Просмотры 0 предпросмотр

Войдите, чтобы отмечать, делиться и комментировать!
Ankit Chand добавлена новая статья Health
2025-05-14 09:55:31 -

Metastatic Colorectal Cancer Market is Driven by Targeted Therapies
The metastatic colorectal cancer (mCRC) market encompasses a broad spectrum of treatment modalities designed to improve survival outcomes and quality of life for patients with advanced disease. Key products include monoclonal antibodies, tyrosine kinase inhibitors, immunotherapies, and personalized combination regimens that target specific genetic mutations such as KRAS, NRAS, and BRAF. These...

0 Комментарии 0 Поделились 630 Просмотры 0 предпросмотр

Войдите, чтобы отмечать, делиться и комментировать!
Sanket Khaire добавлена новая статья Другое
2025-05-27 10:40:19 -

Metastatic Prostate Cancer Market Driven by Targeted Therapies
The metastatic prostate cancer market revolves around therapeutic solutions designed to inhibit tumor growth and spread in advanced-stage prostate cancer patients. Products in this market include androgen receptor inhibitors, radioligand therapies, immunotherapies, and chemotherapeutic agents, each offering unique mechanisms of action and safety profiles. Androgen receptor inhibitors like...

0 Комментарии 0 Поделились 577 Просмотры 0 предпросмотр

Войдите, чтобы отмечать, делиться и комментировать!
Kajalpatil Patil добавлена новая статья Health
2025-04-08 10:34:55 -

Metastatic Prostate Cancer Market is driven by Rising Prevalence of Advanced-Stage Prostate Cancer Cases Globally
The Metastatic Prostate Cancer market encompasses therapeutic solutions, diagnostic tools, and treatment methodologies designed to address advanced-stage prostate cancer that has spread beyond the prostate gland to other parts of the body. This condition requires comprehensive treatment approaches, including hormone therapy, chemotherapy, immunotherapy, and targeted treatments. The market has...

0 Комментарии 0 Поделились 1Кб Просмотры 0 предпросмотр

Войдите, чтобы отмечать, делиться и комментировать!
Kislay Kumar добавлена новая статья Другое
2025-05-05 14:05:40 -

Metastatic Triple-Negative Breast Cancer (mTNBC) Market is driven by targeted therapies
Metastatic triple-negative breast cancer (mTNBC) is a highly aggressive subtype characterized by the absence of estrogen receptors, progesterone receptors, and HER2 expression. Representing roughly 15–20% of all breast cancers, mTNBC poses significant therapeutic challenges due to its heterogeneity, rapid progression, and limited response to hormone- or HER2-directed agents. Current...

0 Комментарии 0 Поделились 774 Просмотры 0 предпросмотр

Войдите, чтобы отмечать, делиться и комментировать!
Kislay Kumar добавлена новая статья Другое
2025-06-06 06:57:58 -

Metastatic Triple-Negative Breast Cancer Market is driven by Market Growth
The Metastatic Triple-Negative Breast Cancer (mTNBC) market focuses on specialized therapies designed to target rapidly progressing, treatment-resistant breast tumors lacking estrogen, progesterone, and HER2 receptors. Key products include PARP inhibitors, immune checkpoint inhibitors, antibody-drug conjugates, and combination regimens that offer advantages such as improved progression-free...

0 Комментарии 0 Поделились 502 Просмотры 0 предпросмотр

Войдите, чтобы отмечать, делиться и комментировать!
Khushbu Coherent добавлена новая статья Health
2025-04-30 11:43:10 -

Neuroendocrine Prostate Cancer Market to Grow Rapidly with Targeted Therapeutics
The Neuroendocrine Prostate Cancer (NEPC) market encompasses a range of novel therapies such as somatostatin analogs, peptide receptor radionuclide treatments, small-molecule inhibitors, and monoclonal antibodies designed to target hormone-resistant and neuroendocrine-differentiated prostate tumors. These products offer improved specificity by exploiting neuroendocrine markers, potentially...

0 Комментарии 0 Поделились 727 Просмотры 0 предпросмотр

Войдите, чтобы отмечать, делиться и комментировать!